The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis
Open accessAbstract
BACKGROUND: Tuberculous meningitis is often lethal. Early antituberculosis treatment and adjunctive treatment with glucocorticoids improve survival, but nearly one third of patients with the condition still die. We hypothesized that intensified antituberculosis treatment would enhance the killing of intracerebral Mycobacterium tuberculosis organisms and decrease the rate of death among patients. METHODS: We performed a randomized, double-blind, placebo-controlled trial involving human immunodeficiency virus (HIV)-infected adults and HIV-uninfected adults with a clinical diagnosis of tuberculous meningitis who were admitted to one of two Vietnamese hospitals. We compared a standard, 9-month antituberculosis regimen (which included 10 mg of rifampin per kilogram of body weight per day) with an intensified regimen that included higher-dose rifampin (15 mg per kilogram per day) and levofloxacin (20 mg per kilogram per day) for the first 8 weeks of treatment. The primary outcome was death by 9 months after randomization. RESULTS: A total of 817 patients (349 of whom were HIV-infected) were enrolled; 409 were randomly assigned to receive the standard regimen, and 408 were assigned to receive intensified treatment. During the 9 months of follow-up, 113 patients in the intensified-treatment group and 114 patients in the standard-treatment group died (hazard ratio, 0.94; 95% confidence interval, 0.73 to 1.22; P=0.66). There was no evidence of a significant differential effect of intensified treatment in the overall population or in any of the subgroups, with the possible exception of patients infected with isoniazid-resistant M. tuberculosis. There were also no significant differences in secondary outcomes between the treatment groups. The overall number of adverse events leading to treatment interruption did not differ significantly between the treatment groups (64 events in the standard-treatment group and 95 events in the intensified-treatment group, P=0.08). CONCLUSIONS: Intensified antituberculosis treatment was not associated with a higher rate of survival among patients with tuberculous meningitis than standard treatment. (Funded by the Wellcome Trust and the Li Ka Shing Foundation; Current Controlled Trials number, ISRCTN61649292.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and Adults
Thwaites, G. E., Bang, N. D., Dung, N. H., Quy, H. T., Oanh, D. T. T., Thoa, N. T. C., Hien, N. Q., Thuc, N. T., Hai, N. N., Lan, N. T. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040573 · Cited by 1,043
Self-citationTuberculous meningitis: a uniform case definition for use in clinical research
Marais, S., Thwaites, G., Schoeman, J. F., Török, M. E., Misra, U. K., Prasad, K., Donald, P. R., Wilkinson, R. J., & Marais, B. J. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70138-9 · Cited by 932
Self-citationDexamethasone for treatment of tuberculous meningitis in adolescents and adults
Tunkel, A. R. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0059-0 · Cited by 671
Thwaites, G., Fisher, M., Hemingway, C., Scott, G., Solomon, T., & Innes, J. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.06.011 · Cited by 666
Self-citationFour-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Gillespie, S. H., Crook, A. M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murray, S. R., Pappas, F., Phillips, P. P. J., & Nunn, A. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407426 · Cited by 645
Corticosteroids for managing tuberculous meningitis
Prasad, K., Singh, M. B., & Ryan, H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002244.pub4 · Cited by 534
Tuberculous meningitis: more questions, still too few answers
Thwaites, G. E., van Toorn, R., & Schoeman, J. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70168-6 · Cited by 482
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Jindani, A., Harrison, T. S., Nunn, A. J., Phillips, P. P. J., Churchyard, G. J., Charalambous, S., Hatherill, M., Geldenhuys, H., McIlleron, H. M., Zvada, S. P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314210 · Cited by 432
A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
Merle, C. S., Fielding, K., Sow, O. B., Gninafon, M., Lo, M. B., Mthiyane, T., Odhiambo, J., Amukoye, E., Bah, B., Kassa, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315817 · Cited by 399
Ruslami, R., Ganiem, A. R., Dian, S., Apriani, L., Achmad, T. H., van der Ven, A. J., Borm, G., Aarnoutse, R. E., & van Crevel, R. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70264-5 · Cited by 344
Role of individual drugs in the chemotherapy of tuberculosis.
Mitchison, D. A. (2000) · PubMed · Cited by 319
Torok, M. E., Yen, N. T. B., Chau, T. T. H., Mai, N. T. H., Phu, N. H., Mai, P. P., Dung, N. T., Chau, N. V. V., Bang, N. D., Tien, N. A., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir230 · Cited by 312
Self-citationA Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Boeree, M. J., Diacon, A. H., Dawson, R., Narunsky, K., du Bois, J., Venter, A., Phillips, P. P. J., Gillespie, S. H., McHugh, T. D., Hoelscher, M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1264oc · Cited by 309
Cerebrospinal fluid concentrations of antituberculosis agents in adults and children
Donald, P. R. (2010) · Tuberculosis · doi:10.1016/j.tube.2010.07.002 · Cited by 222
Johnson, J. L., Hadad, D. J., Boom, W. H., Daley, C. L., Peloquin, C. A., Eisenach, K. D., Jankus, D. D., Debanne, S. M., Charlebois, E. D., Maciel, E. L. N., et al. (2006) · PubMed · Cited by 200
Peloquin, C. A., Hadad, D. J., Molino, L. P. D., Palaci, M., Boom, W. H., Dietze, R., & Johnson, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01036-07 · Cited by 185
The Diagnosis and Therapy of Tuberculosis During the Past 100 Years
Mitchison, D. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1603oe · Cited by 185
Cerebrospinal Fluid Drug Concentrations and the Treatment of Tuberculous Meningitis
Ellard, G. A., Humphries, M. J., & Allen, B. W. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/148.3.650 · Cited by 141
Thwaites, G. E., Bhavnani, S. M., Chau, T. T. H., Hammel, J., Török, M. E., Wart, S. A. V., Phuong, P., Reynolds, D. K., Caws, M., Dung, N. T., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00064-11 · Cited by 136
Self-citationArdito, F., Posteraro, B., Sanguinetti, M., Zanetti, S., & Fadda, G. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.12.4440-4444.2001 · Cited by 127
Dexamethasone and Long-Term Outcome of Tuberculous Meningitis in Vietnamese Adults and Adolescents
Török, M. E., Bang, N. D., Chau, T. T. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027821 · Cited by 94
Self-citationPenetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges
Nau, R., Prange, H. W., Menck, S., Kolenda, H., Visser, K., & Seydel, J. K. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/29.6.719 · Cited by 85
Brake, L. T., Dian, S., Ganiem, A. R., Ruesen, C., Burger, D. M., Donders, R., Ruslami, R., van Crevel, R., & Aarnoutse, R. E. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.12.027 · Cited by 82
Heemskerk, D., Day, J., Chau, T. T. H., Dung, N. H., Yen, N. T. B., Bang, N. D., Merson, L., Olliaro, P., Pouplin, T., Caws, M., et al. (2011) · Trials · doi:10.1186/1745-6215-12-25 · Cited by 70
Self-citationThe chemotherapy of tuberculous meningitis in children and adults
Donald, P. R. (2010) · Tuberculosis · doi:10.1016/j.tube.2010.07.003 · Cited by 66
Wolbers, M., Heemskerk, D., Chau, T. T. H., Yen, N. T. B., Caws, M., Farrar, J., & Day, J. (2011) · Trials · doi:10.1186/1745-6215-12-26 · Cited by 25
Self-citation
Cited by
Corticosteroids for managing tuberculous meningitis
Prasad, K., Singh, M. B., & Ryan, H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002244.pub4 · Cited by 534
on behalf of the Tuberculous Meningitis International Research Consortium, Wilkinson, R. J., Rohlwink, U., Misra, U. K., van Crevel, R., Mai, N. T. H., Dooley, K. E., Caws, M., Figaji, A., Savic, R., et al. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.120 · Cited by 508
Self-citationTiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 396
Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30274-2 · Cited by 379
Cresswell, F. V., Tugume, L., Bahr, N. C., Kwizera, R., Bangdiwala, A. S., Musubire, A. K., Rutakingirwa, M., Kagimu, E., Nuwagira, E., Mpoza, E., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30550-x · Cited by 124
Metadata
- Authors
- Heemskerk, A. D., Bang, N. D., Mai, N. T. H., Chau, T. T. H., Phu, N. H., Loc, P. P., Chau, N. V. V., Hien, T. T., Dung, N. H., Lan, N. T. N., Lan, N. H., Lan, N. N., Phong, L. T., Vien, N. N., Hien, N. Q., Yen, N. T. B., Ha, D. T. M., Day, J. N., Caws, M., Merson, L., Thinh, T. T. V., Wolbers, M., Thwaites, G. E., & Farrar, J. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-01-14
- Volume
- 374
- Issue
- 2
- Pages
- 124-134
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2333921168
- Cited by
- 310
- References
- 27
- FWCI
- 41.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.